Sign in

    Brian Conley

    Research Analyst at Leerink Partners

    Brian M. Conley, Ph.D., is an Equity Research Analyst at Leerink Partners, specializing in diversified biopharmaceuticals with a focus on immunology and emerging biotechnology companies. He covers companies such as 89bio, Abivax, and Aclaris Therapeutics, actively publishing ratings and financial projections for these firms. Dr. Conley joined Leerink Partners following advanced academic training and holds FINRA registration, maintaining compliance with key securities licenses. With a research-driven approach and notable expertise in healthcare equities, he contributes actionable insights to institutional investors within the evolving biotech sector.

    Brian Conley's questions to ARGENX (ARGX) leadership

    Brian Conley's questions to ARGENX (ARGX) leadership • Q1 2024

    Question

    Brian Conley, on behalf of Tom Smith, asked about efgartigimod's competitive positioning in thyroid eye disease (TED), any differentiating aspects of its Phase III trial design, and plans for chronic TED.

    Answer

    CEO Tim Van Hauwermeiren stated that the Phase III TED program is actively enrolling globally. He noted the trial design is similar to competitors but also includes a capped number of patients who have previously been treated with Tepezza. He also mentioned the study is utilizing the prefilled syringe but deferred further strategic details.

    Ask Fintool Equity Research AI